The University of Connecticut is looking at possible measures to address a $134 million budget deficit for fiscal year 2026, including reducing staff, restricting travel, events and activities, and ...

Advanced technologies and close collaboration maximize yields, safety, and patient access to life-saving therapies.

The Food and Drug Administration (FDA) has approved 2 additional vial sizes of Niktimvo ™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size. Niktimvo, a colony stimulating ...

The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug ...

(RTTNews) - Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies ...

The FDA has granted approval to axatilimab-csfr (Niktimvo) in 9 mg and 22 mg vial sizes. Currently, axatilimab is an approved treatment for patients with chronic graft-vs-host disease (GVHD) after ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims. Photo by Adobe Stock ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims. About 6% of Leqembi ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims. Photo by Adobe Stock/HealthDay ...

14, 2024 (HealthDay News) -- A simple tweak in available vial sizes of the breakthrough Alzheimer’s drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims.